Comparison of the effects of novel vitamin D receptor analog VS-105 and paricalcitol on chronic kidney disease-mineral bone disorder in an experimental model of chronic kidney disease
详细信息 查看全文
- 作者：Hideki Fujii ; fhideki@med.kobe-u.ac.jp ; Yuriko Yonekura ; Kentaro Nakai ; Keiji Kono ; Shunsuke Goto ; Shinichi Nishi
- 关键词：VS-105 ; Vitamin D analog ; CKD-MBD ; FGF23 ; Klotho
- 刊名：The Journal of Steroid Biochemistry and Molecular Biology
- 出版年：2017
- 出版时间：March 2017
- 年：2017
- 卷：167
- 期：Complete
- 页码：55-60
- 全文大小：816 K
- 卷排序：167
文摘
VS-105 is a novel VDRA which has lesser effects on serum calcium levels. Serum P levels were higher in the paricalcitol-treated groups than in the VS-105-treated groups. The urinary excretion of P was lower in the paricalcitol-treated groups than in the VS-105-treated groups. VS-105 affects serum FGF23 levels less than did paricalcitol. VS-105 ameliorates the VDR and Klotho expression in the kidney more than paricalcitol.